Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD

B7-33 2mg Pre-Mixed Peptide


B7-33 2mg Premixed Peptide has powerful anti-fibrotic properties. Chronic and acute diseases like heart failure, inflammation of the lungs or the kidneys can all be helped by reducing fibrosis. B7-33 has been shown in animal studies to minimise fibrosis resulting in prolonged survival following injury and providing the treatment for heart failure.

Pre Mixed Cartridge and Kit:

  • 1 x Cartridge (The cartridge is premixed with the peptide vial of your choice and Bacteriostatic Water)
  • 1 x Peptide Cartridge Pen
  • 1 x Pen Carry Case
  • 3 x Pen Needle Tips

Single Mixed Cartridges (1,2 & 3) Come with:

  • 1,2 or 3 x Cartridge (The cartridge is premixed with the peptide vial of your choice and Bacteriostatic Water)
  • 3 x Pen Needle Tips

The single 1,2 & 3 cartridges do not come with a kit.

Buy 10 and get 10% Discount

499 in stock


B7-33 2mg Pre-mixed Peptide New Zealand

This product is intended for research purposes only. To be used by trained professionals only.

B7-33 is a synthetic peptide produced from human relaxin-2, a hormone that regulates various physiological processes such as vascular function, inflammation, and tissue repair. B7-33 has been proven to mimic the vasoprotective effects of human relaxin-2 and to offer therapeutic promise in a variety of disease conditions.

B7-33 has been proven in studies to improve tissue healing and minimise fibrotic encapsulation. One study discovered that coatings containing B7-33 2mg pre-mixed peptide could minimise fibrotic encapsulation in implanted devices, implying that the peptide has the potential to improve the biocompatibility of such devices [1]. B7-33 has also been demonstrated to inhibit the development of endothelial dysfunction, indicating its potential use in the treatment of cardiovascular disorders.

Furthermore, B7-33 peptide has been shown in mice to prevent adverse cardiac remodelling following a myocardial infarction (MI). Long-term dosing of B7-33 improved cardiac function and reduced fibrosis in rats with MI, showing that the peptide may have therapeutic potential in the treatment of heart disease [2].

B7-33 has also been researched for its ability to inhibit pancreatic cancer liver metastasis. A lipidated derivative of B7-33 was discovered to extend the peptide’s half-life in vivo and improve its efficacy in preventing cancer cell migration and invasion. This suggests that B7-33 2mg pre-mixed peptide may have therapeutic uses in cancer treatment [3].

Overall, B7-33 has demonstrated encouraging outcomes in tissue regeneration, fibrosis and inflammation reduction, and cardiovascular health improvement. However, more New Zealand research is needed to fully understand the mechanisms of action of this peptide and its potential applications.


[1] https://pubmed.ncbi.nlm.nih.gov/ 31713411/

[2] https://www.ahajournals.org/ doi/10.1161/JAHA.119.015748

[3] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC7674520/


Storage: Lyophilized peptides stored below -18°C

Research use only. Not for human or animal consumption!

B7-33 HPLC 2023 Certificates_DIRECT PEPTIDES










DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our New Zealand Direct Peptides website: https://new-zealand.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.

BUY B7-33 2mg Pre-Mixed Peptide ONLINE today From New Zealand Direct Peptides

You may also like…